Ключевые слова:
ишемическая болезнь сердца, розувастатин, липидный спектр, Толщина интима-медиаБиблиографические ссылки
Adji A.S., Billah A., Nugraha A., Sit J.E.P., et al. Lipid Profile and Safety of Rosuvastatin Monotherapy versus Rosuvastatin plus Ezetimibe: A Meta-Analysis. Egypt Heart J. 2025; 77:58.
Dose Study of Rosuvastatin Calcium in the Treatment of Coronary Heart Disease and Hyperlipidemia: Retrospective Study in Elderly Patients. 2020.
Kim H.-L., Joh H.S., Kim S.-H., Kim M.-A. Real-World Effectiveness of Rosuvastatin–Ezetimibe Single Pill (Rovazet®) in Korean Dyslipidemia Patients. J Clin Med. 2025;14(15):5480.
Patnaik P.K., et al. Effectiveness and Safety of Rosuvastatin in Reducing LDL Cholesterol Levels: An Observational Study. Eur J Cardiovasc Med. 2024; 14(2):935-940.
REAL ROSE": Real-World Clinical Experience of Rosuvastatin for Primary and Secondary Prevention of Cardiovascular Events. Cureus. 2022; 14(11):e31468.
Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study. PubMed. 2022. PMID: 35746323.
Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk. J Clin Med. 2024;13(7):1894.
Saeed M., et al. Clinical Efficacy of Ezetimibe Combined with Rosuvastatin in Hypercholesterolemia Inadequately Controlled by Statin Therapy. Br J Hosp Med. 2024.
Turaeva Z., Khodjaeva D., Akhmedova N. Obesity, Burden of Ischemic Heart Diseases and Their Ecological Association: The Case of Uzbekistan. Int J Environ Res Public Health. 2022;19(21):14252.
Ye F., Chen H., Li H. Incidence of Coronary In-Stent Restenosis and LDL-C Goal Achievement in Type 2 Diabetes Mellitus Patients Treated with Ezetimibe plus Rosuvastatin. Front Cardiovasc Med. 2025;12:1599313.